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WE report the regulation of type 1 receptor mRNA
in Y-79 human retinoblastoma cells, grown in the
absence or presence of pharmacological levels of
phorbol esters, forskolin, glucocorticoids and
their combinations. To control for inducibility
and for assessing the sensitivity of the Y-79
system to glucocorticoids, corticotropin releasing
hormone mRNA levels were measured in parallel.
All treatments stimulated corticotropin releasing
hormone receptor type 1 gene expression relative
to baseline. A weak suppression of corticotropin
releasing hormone mRNA level was observed
during dexamethasone treatment. The cell line
expressed ten-fold excess of receptor to ligand
mRNA under basal conditions. The findings pre-
dict the presence of functional phorbol ester,
cyclic AMP and glucocorticoid response elements
in the promoter region of corticotropin releasing
hormone receptor type 1 gene and support a
potential role for its product during chronic
stress and immune/inflammatory reaction.
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Introduction
Stress response (the organism’s ability for adap-
tive homeostasis) is a major survival resource
and an important permissive factor of primal
life properties such as growth, reproduction,
evolution and adaptation. In mammals, unex-
pected stimulation or stress, activates the heat
shock protein (hsp) system at the cellular level,
and the hypothalamic-pituitary-adrenal (HPA)
axis at the level of the whole organism. At the
molecular level, these two systems communi-
cate through the functional interaction between
hsp90 and glucocorticoid receptor (GR).
2
Glucocorticoids are final effectors of the axis,
that bind and activate GRs to exert negative
feedback regulation at multiple levels of
the axis including the proopiomelanocortin
(POMC)3 and corticotropin releasing hormone
receptor (CRHR) type 1 genes
4 in the anterior
pituitary corticotroph, and the corticotropin
releasing hormone (CRH) gene in the
paraventricular nucleus (PVN) of the hypo-
thalamus.5 The CRH system, including the
hormone
6 and urocortinv ligands, their two
receptor types" type 18-11 expressed primarily
in the brain,
12 and type 213-15 with its two
splice variant isoforms; z expressed in limited
areas of the brain
14 and [3 expressed in periph-
eral tissues including the duodenum, skeletal
muscle, epididymis and perivascular cells of the
1316 heart, and the binding protein (CRHBP),
7 is
central coordinator of HPA axis activity and acts
in concert with glucocorticoids to maintain
whole body homeostasis.
Animal studies revealed highly complex reg-
ulation and tissue-specific expression patterns
of CRH system components, using a variety of
512.’16 18 21 molecular probes.’ To this end, studies
with cell lines expressing components of the
CRH system, either naturally or following trans-
fection, provide valuable alternatives to the
multiparametric complexity inherent in the ani-
mal model systems approach and complement
molecular analyses of critical regulatory as-
pects.
22-25
The human retinoblastoma cell line Y-79,
expresses functional CRHRs.26 We report the
effect of forskolin, phorbol esters, dexametha-
sone and their combinations, on CRHR type 1
mRNA levels in Y-79 cells, using CRH mRNA
coexpression as induction control.
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Materials and Methods
Cell line and culture conditions
Y-79 is a suspension culture distributed by
American Type Culture Collection. The cell line
was adopted to growth in steroid-free synthetic
media containing antibiotics (CHO-S-SFM, Gibco
-BRL Inc.). We assessed that growth under these
conditions, does not impair the expression of
CRHR. For that, we reacted biotinylated CRH
tracer to protein homogenates immobilized
onto nitrocellulose filters. Tracer binding was
competed with excess CRH but not with
dynorphin or growth hormone releasing hor-
mone competitors (data not shown). Binding of
biotinylated tracer was recorded on X-ray film
by means of a chemiluminescent based detec-
tion system (New England Biolabs Inc.). Con-
centrated cell suspensions were added to 100
excess of fresh media, and induced by phorbol
esters (T; to 100 ng/ml), forskolin (F; to 25 bM),
dexamethasone (D; to 10-6 M) and their combi-
nations to the indicated final concentrations.
Following addition of the appropriate inducers,
the cell suspensions were incubated at 37C in
95% CO2-5% air for 3 days. Inductions and
controls were performed in triplicate. By ana-
logy to other cell lines,24’27 these treatments had
no toxic effect to the cultured Y-79 cells.
Preparation of DNA probes
The probe used for CRHR type 1 mRNA
hybridization was a 371 bp long fragment of the
3’ non-coding region of the human CRHR type
1 gene that was prepared by direct polymerase
chain reaction (PCR) amplification of total hu-
man genomic DNA template as described.
28 We
used a 785 bp long fragment of CRH cDNA
spanning from position 1 (A of the initiator
AUG codon) to 785 (in the 3’ non-coding
region) according to the numbering system of
Shibahara et al.,29 as a hybridization probe for
CRH mRNA. This fragment was amplified by
PCR in a 50 bl reaction containing 50 ng clone
11 DNA template (human genomic CRH plas-
mid), 50 nmol of each primer (hCtI-If(l_22)"
5’-ATGCGGCTGCCGCTGCTTGTGT-3’ and
hCRI-Ir(754-785): 5’-GTGTTGCTGCTGCACGTGAA-
TACAcTTTGTCG-3’) and Stratagene’s DNA poly-
merase and buffer system, for 30 cycles
(denaturation at 94C for 1 rain, annealing at
58C for 30 s, and extension at 72C for 1 min).
The PCR reaction products were fractionated
on agarose gels and the 371bp CRHR and
785 bp CRH cDNA fragments were gel purified,
quantitated, and P32-1abelled by nick translation,
27 as described. Both probes were labelled to
similar specific activities. Preparation and use of
human [3 actin cDNA probe for normalization of
Northern data, was as previously described.
27
Northern blot analysis
Preparation of total cytoplasmic RNA, was
performed as previously described.27 Signal
strength was assessed by direct counting wet
filters by means of a horizontal radioactivity
counting device (Betascope 603 blot analyser,
Betagen, Waltham, MA), as described.27 All ana-
lyses were performed in triplicate and the fold
inductions obtained were within 10% from the
mean. Representative mean total RNA prepara-
tions for every experimental condition, were
prepared by combining equal (spectrophoto-
metrically) amounts of RNA from each triplicate
point, and this report summarizes the Northern
data generated by these pooled samples.
Materials
The sources of the various reagents used in this
study, were as follows: Cells (ATTC, Rockville,
MD), tx-32p-dCTP (3 000 Ci/mmol, ICN, Costa
Mesa, CA, USA), random primer nick translation
kit (Amersham, Arlington Heights, IL, USA),
culture media, antibiotics, ethidium bromide
and RNA size standards (Gibco-BRL Life Tech-
nologies Inc., Gaithersburg, MD), 12-O-tetra-
decanoylphorbol 13-acetate (T), forskolin (F) and
dexamethasone (D) inducers (Sigma, St Louis,
MO), DNA polymerases for PCR amplification
(Stratagene, La Jolla, CA and Perkin Elmer-Cetus,
Foster City, CA), peptides (Peninsula Labs Inc.,
Belmont, CA), qbX-174 HaelII digested DNA size
standards and chemiluminescent based detec-
tion system (New England Biolabs, Beverly,
MA), Kodak XR X-ray film and intensifying
screens (Eastman Kodak, Rochester, NY).
Results
Induction of CRHR type mRNA
Equal portions of a concentrated suspension of
Y-79 cells were diluted 100 with fresh media,
the indicated amounts of inducer(s) T, E
D, T+E T+D, F+D, T+F+D were added,
and incubated at 37C for 3 days. Each induc-
tion was performed in triplicate. Following
treatment, the cells were collected, washed in
PBS, and total RNA was extracted as
27 described. For each condition, triplicate total
RNA quantitations were made, yielding minor
variations by about 10% from the mean, and
equal portions were combined to yield a pooled
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total RNA sample per condition. Northern
analyses of these pooled samples are shown in
Figs 1 and 2.
The quality of pooled total RNA from each
treatment group, was assessed by pilot agarose
gel electrophoresis using 1 bg RNA per lane,
along with RNA size standards. A representative
preparation is shown in Fig. 1A. The ethidium
bromide staining pattern of the eight different
RNAs, suggested that the preparations con-
tained primarily intact .material.
The degree of induction of CRHR type 1 gene
expression, was determined by hybridization of
the Northern blotted gel containing 20 bg of
total RNA per lane, to a 371 bp long fragment
of the 3’ non-coding region of CRHR type 1
DNA that was prepared by direct PCR amplifica-
tion of human total genomic DNA template.
2s
The results are shown in Fig. lB. All the
inducers elevated CRHR type 1 mRNA relative
to control. Dexamethasone was the most potent
single stimulant, producing a maximal 4.5-fold
increase in CRHR type 1 mRNA level alone or
in combination with E and a 3.5-tbld increase in
CRHR type 1 mRNA when D induction was
made in the presence of T and T / E Fig. lB.
Induction of CRH mRNA
The induction of CRH mRNA by forskolin/PKA,
phorbol esters/PKC and glucocorticoid path-
ways has been reviewedi1 The Y-79 cell system
expresses detectable amounts of CRH mRNA by
Northern blotting (novel finding of this study).
We therefore measured CRH mRNA levels in
order to assess the responsiveness of the Y-79
cells to the various treatments as well as the
relative levels of receptor and ligand and their
responses to common inducers.
CRH mRNA detection, was made on a dupli-
cate blot to that used for CRHR type 1 mRNA
analysis. The probe used for hybridization, was
a 785bp DNA segment of the CRH gene
including all the protein coding region and a
small portion of the 3’ non-coding region of
exon 2, that was amplified from clone 11, a
genomic clone containing the human CRH gene
and its flanking regions; as detailed in the
Methods section.
Ethidium bromide staining of the electro-
phoretic pattern of the PCR reaction product, is
shown in Fig. 2A. Co-induction of CRH mRNA
level, is shown in Fig. 2B. Long exposures (8
days) were used to detect CRH mRNA signals. A
five-fold excess of receptor to ligand cpm was
detected in non induced Y-79 cells, by means of
the betascope. This difference might be closer
to tenfold taking into account the nearly two-
fold size difference between CRHR type 1 and
CRH cDNA probes used for Northern blotting
detection. The effect of inducers and particu-
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FIG. 1. Induction of CRHR type mRNA. (A) Pilot fractionation of #g total cytoplasmic RNA per lane stained with ethidium
bromide. The cells were induced by T (phorbol esters); F (forskolin); D (dexamethasone), and their combinations as indicated
on each lane. (B) Northern blot containing 20 #g per lane total cytoplasmic RNA from Y-79 cells treated as indicated, was
hybridized to the 371 bp hCRHR-specific DNA type probe that had been prepared by PCR.
28 The blot was stripped and
reprobed with an actin probe, and the normalized induction-fold values measured by direct quantitation are shown below
each lane.
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FIG. 2. Induction of CRH mRNA. (A) Electrophoretic pattern of the 785 bp CRH cDNA PCR fragment that was used as a probe,
along 4pX-174 Haelll DNA size standards. (B) Northern blot containing 20 #g per lane total cytoplasmic RNA from Y-79 cells
treated as indicated, was hybridized to the 785 bp long hCRH-specific DNA probe that had been prepared by PCR. The blot
was stripped and reprobed with an actin probe. Signal strengths were measured by direct horizontal quantitation of the
27 filters, as described. The normalized induction-fold values are shown below each lane.
suggests that Y-79 cells are of hypothalamic
PVN type and not of placental or central
nucleus of the amygdala type, tissues where
glucocorticoids upregulate CRH gene expres-
sion.5’18-19 This is also supported by the com-
mon glucocorticoid upregulation of CRHR type
4 20 1 mRNA in rat hypothalami and Y-79 cells.
Discussion
We studied the regulation of CRHR type 1
mRNA in Y-79 human retinoblastoma cells by
phorbol esters, forskolin, glucocorticoids and
their combinations, using CRH gene coexpres-
sion as internal control. Given the comparable
processing of the filters shown in Figs 1 and 2,
the observed background of the Northern blot
of Fig. 1, suggests most probably the detection
of additional transcripts with homology to
CRHR type 1 mRNA (i.e. CRHR type 2 mRNA
with 70% homology,s etc.). Although it could be
argued that the background may affect the
accuracy of the calculated induction values, the
observed direction of CRHR type 1 mRNA
induction trends remains informative. In the
absence of regulatory interference by vasopres-
sin, oxytocin and other neuroendocrine factors,
glucocorticoids, suppressed CRH, and stimu-
lated CRHR type 1 gene expression, in the Y-79
environment. In line with HPA axis regulation,
glucorticoids, appear to suppress CRH and
stimulate CRHR type 1 gene expression in the
4 19-20 PVN of rat hypothalamus. This correlation
weakens the possibility of potential cell line
dependent regulatory artifacts and predicts that
glucocorticoids may also stimulate human hy-
pothalamic CRHR type 1 gene expression. We
cannot exclude the possibility that dexametha-
sone, a well-known apoptotic factor, may have
triggered apoptosis in our system, causing
induction of gene expression, not necessarily in
line with the HPA regulatory system. However,
apoptosis of human lymphocytes, known for
their enhanced sensitivity to glucocorticoids,
was not seen at the level of the hsp90 system
27- under similar culture conditions, excluding
indirectly this possibility in the present Y-79
cellular suspension culture system.
In addition to glucocorticoids, forskolin and
phorbol esters stimulated both receptor and
ligand gene expression, suggesting the presence
of functional protein kinase A (PKA) and c(PKC)
signal transduction pathways in Y-79 cells, as
well as the presence of functional phorbol ester
(TRE), cyclic AMP (eRE) and glucocorticoid
response elements (GRE) in the promoter region
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of CRHR type 1 gene. Combined treatments
were used to sustain and confirm the overall
primary response trends of CRHR type 1-1igand
genes in the Y-79 cell system. Maximal induction
for the CRHR type 1 gene was five-fold and for
the CRH gene two-fold. These differences may
reflect either the relative potencies of the
response elements between the two genes, or
the presence of novel receptor-specific response
element(s). Basally, Y-79 express ten-fold excess
of receptor to ligand mRNA, suggesting a poten-
tially inverse autonomous regulation of ligand
expression by the receptor.32 We have not
determined whether ligand may also regulate
receptor expression in this system.
Our finding of CRHR type 1 mRNA up-
regulation with concomitant CRH mRNA down-
regulation by dexamethasone in the Y-79 human
retinoblastoma cell line, underscores the regula-
tory plasticity of the CRH system for the
maintenance and/or restoration of homeostasis.
The potential biological significance of this
observation may be that during classical hyper-
cortisolaemic states such as pregnancy, depres-
sion or Cushing’s disease,3 the selective
elevation of CRHR type 1 (i.e. in the
hypothalamus,4’2 or other sites) may increase
the sensitivity of the CRH system and prime, the
organisms homeostatic rebound response.4 By
analogy to immune CRH,1 local elevation of
immune CRHR type 1 in inflammatory sites,
such as the arthritic joints of patients with
rheumatoid arthritis, may increase the sensitiv-
ity of the immune CRH system and prime
homeostatic rebound response at the local level.
This mechanism, may also account for the
beneficial effect of local glucocorticoid adminis-
tration to inflammatory sites. Further studies on
the regulation of CRHR type 2 gene expression
by dexamethasone will be needed to support
such correlational generalizations.
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